Suzanne J. Romano, PhD
SVP, Product Evaluation & Early-Stage Development
Dr. Romano is responsible for evaluation, preclinical and early clinical development of HUYABIO’s in-licensed drug candidates sourced from China. Having participated in all aspects of HUYABIO’s in-licensing process, including initial assessment, due diligence, partnering agreements, alliance management, and execution of development plans, she is currently responsible for the clinical proof of concept trials for HUYABIO’s lead cardiovascular asset, HBI-3000. With over 25 years industry experience, Dr. Romano has skills in drug discovery, preclinical development, corporate partnering, and alliance management, in a broad range of therapeutic areas, including oncology, diabetes, inflammation, and CNS disorders, and has provided scientific business development consulting services to several biotech companies. She was previously Director, Business Development at Novasite Pharmaceuticals, served in corporate development and drug discovery positions at Ontogen Corporation and was a member of the biotechnology product development group at J&J. Dr. Romano received a PhD in Biology/Neurobiology from University of California, San Diego, and an AB in Biology from Princeton University.